Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase - Wikidata - wikimedia - TriplyDB

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

http://www.wikidata.org/entity/Q34896117

about

Developments in the scientific and clinical understanding of gout Pegloticase for chronic gout Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout The emerging role of biotechnological drugs in the treatment of gout Anti-PEG immunity: emergence, characteristics, and unaddressed questions.Site-specific functionalization of proteins and their applications to therapeutic antibodies Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy Evolutionary history and metabolic insights of ancient mammalian uricases PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study Emerging PEGylated drugs.Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers Reassessing serum urate targets in the management of refractory gout: can you go too low?Expression and function of CXCL16 in a novel model of gout.Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.Immunogenicity to biologics: mechanisms, prediction and reduction.Comparison of activity indexes for recognizing enzyme mutants of higher activity with uricase as model Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS Rapid Light-Triggered Drug Release in Liposomes Containing Small Amounts of Unsaturated and Porphyrin-Phospholipids.Uricases as therapeutic agents to treat refractory gout: Current states and future directions.A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties Synthesis and in vivo pharmacokinetic evaluation of degradable shell cross-linked polymer nanoparticles with poly(carboxybetaine) versus poly(ethylene glycol) surface-grafted coatings.Effects of glycosylation on the stability of protein pharmaceuticals.Critical appraisal of the role of pegloticase in the management of gout.A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.Delivery of therapeutic proteins.Drug delivery technologies for autoimmune disease.New advances in the treatment of gout: review of pegloticase The hope and reality of long-acting hemophilia products.Pegloticase: a novel agent for treatment-refractory gout.Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives.Challenges and approaches for the development of safer immunomodulatory biologics.The immunogenicity of polyethylene glycol: facts and fiction.PEGylated drugs in rheumatology--why develop them and do they work?Optimizing current treatment of gout.Changing paradigm of prophylaxis with longer acting factor concentrates.Surface tailoring of nanoparticles via mixed-charge monolayers and their biomedical applications.

P2860

Q21195376-4E5F6496-C35C-44D8-BB4D-38E60BAFF2C7 Q24236711-F20C626C-922A-4129-859F-D67404956433 Q24673444-17E4C64C-C821-4C12-9BE1-A17E81FC19F8 Q26825459-E445C376-D455-4157-857D-D2F934A0C553 Q26825556-7452C1AE-AAE3-4D4B-A102-D3B20DCFFD95 Q26830699-5456EFF0-F4A8-47BA-926C-5447DEC8CA71 Q27000048-2D158C36-CA62-42D7-A2A6-61943C19B5E8 Q27681817-A5B58D73-0A71-4F95-B6A5-F71431466482 Q27691352-DEA1FFD1-FA20-47F0-84E5-6582C8EC05D6 Q28727969-2A59CE30-58CB-42E6-A481-DF627D8332DC Q30480705-48299DA2-12D3-4E5A-96C0-656A2EDD414F Q33447691-A5CE9F77-6F5D-42EA-A6CE-3E0F88F5983B Q33766720-5B49BFA2-13D1-445C-9B09-AE8464692E15 Q33832781-A2FA78DC-0142-4092-8600-7C4707961281 Q34061506-EF412FE9-751B-48EF-A5DD-FAB465822933 Q34063348-C1896515-C871-4EA8-B612-6E39353F9BD0 Q34069534-C616C9F6-3885-4E1E-A879-8284D77AC91B Q34296526-EF7F667C-205E-43B2-BF03-949F1F8BEF9C Q34675491-2BD40888-E15D-401A-91CF-7CF3E16B30AF Q35843950-A6DE11A6-3EE8-4E5E-95DB-322EBFB1C34D Q36001035-250E016F-CF67-47C3-A5A7-3DC70C07E862 Q36002499-DF1F5A05-2313-4334-B012-8C3082FC4DBC Q36230423-8F248D27-67CF-4EB9-B205-B2F5E183AD75 Q36361709-3F9B9903-E225-4387-8A73-79F8EB000D87 Q37114305-3C16157A-64DD-4F31-A6F2-31311ABB5C9E Q37301152-A2741872-20DF-4CA3-AB47-F25D91D559F5 Q37494353-21F7AB05-D1DC-4076-AAA7-54E7DC27FB6E Q37604498-9EFB5DC7-56E9-41C5-997F-A874F4B8E706 Q37668486-2202A5EE-9794-48FE-8A95-F732CA70932F Q37801381-43967D7F-81C8-4BF5-AFDE-6AC0CA35584B Q37815379-8EF62477-BACA-49CD-A253-B45C6F4F947C Q37990479-AB0AF545-134E-4F9F-882C-D5E9E5A65E49 Q37991129-B0221471-25B3-4FC9-B2EC-12FA137D1C16 Q38020590-D0D93E49-3F63-41FF-9A41-EA1D8AD7A95B Q38093772-7F0B8DA5-B530-4BE2-83DE-B295C7FCF296 Q38106847-AC1BB4EB-C0A2-4E55-B52E-9FA1958B2695 Q38130374-8645E1B1-CC0D-48F5-AE87-B5FAACB5DDB3 Q38194896-44AFF8A1-8ED9-45C8-AFA2-CEE0A80BCC80 Q38206858-3D340728-F7AF-404F-A474-F158BF810E60 Q38239933-20A51AA7-FE8F-4597-A1A4-62A89A5A525E

P2860

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

http://www.wikidata.org/entity/Q34896117

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@ast

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@en

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@nl

type

label

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@ast

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@en

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@nl

prefLabel

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@ast

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@en

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@nl

P1433

Q34896117-275319E6-5DF9-4C7C-9E78-0310BE0F3897

P1476

Q34896117-5620E56C-A04B-42A3-905C-7B1DD0C7FFD6

P2093

Q34896117-00FF5C5D-36D1-45DF-924C-7247CF86366F

Q34896117-362EB87A-6158-480D-BF71-B407D2BD6FB2

Q34896117-562D758F-78C5-4005-B459-B00388BFD948

Q34896117-95389815-DC91-4E14-A5CC-AE7E3930FA36

Q34896117-D41DD855-0026-4C3F-A93C-262F1560610C

P2860

Q34896117-1E025880-846C-4961-B609-85620C6B6FCC

Q34896117-1F0C26B0-0296-4EDB-BB24-E83C462CD85E

Q34896117-2E5D52C2-8A63-41D1-A2DB-3290B3B26EE1

Q34896117-3D314E1D-C645-4FAB-8285-2382499A6DFF

Q34896117-5F4DE7B9-E89B-4B9B-BFE1-C7ED8B004988

Q34896117-65CCA71E-0677-4F7E-9DB6-BACC8B7636C1

Q34896117-71A4F2E2-5AFF-493A-BEA6-F722AFA42676

Q34896117-7C6E9C45-5722-4321-9811-FD81F872130F

Q34896117-8420E9B3-DD72-4122-B5D1-48BE614D706B

Q34896117-84BEF52A-ED68-4BD9-AA3F-A55330B8ADDC

P2888

Q34896117-2B4B876A-7088-4C3B-A669-0654CEFA6F1C

P304

Q34896117-B26B69B6-A203-493A-B6EC-33011F7B7BAF

P31

Q34896117-8350292D-0A9F-4589-BBE7-D96FD0B2A9A3

P356

Q34896117-1BF83452-D17D-4794-B6AC-5A30DE05E86A

P433

Q34896117-6A96D6F7-0A70-4B1D-B6F0-55FFEB837DCC

P478

Q34896117-C85C362A-B58D-462E-BD9D-B24640369BD7

P577

Q34896117-05C0CCE3-7B75-4877-8390-3EDD361CE954

P5875

Q34896117-0CED977E-8573-46A7-BE47-F3F067D68F03

P6179

Q34896117-8A92ADF6-0225-4C93-8B9E-51B8E7850E8E

P698

Q34896117-9205EEC5-C1B4-4704-8CEB-38A1387E16A7

P921

Q34896117-03402C2C-1C0E-4BDE-8452-C842B88EE97B

Q34896117-6382C226-962C-423A-86E5-49DF6F5B55A2

P932

Q34896117-CE267B8F-B495-4B3A-8569-2259EAFF7B03

P356

P1433

Arthritis Research and Therapy

P1476

Control of hyperuricemia in su ...... aneous PEGylated urate oxidase

@en

P2093

Edna Scarlett

http://www.w3.org/2001/XMLSchema#string

John S Sundy

http://www.w3.org/2001/XMLSchema#string

Michael S Hershfield

http://www.w3.org/2001/XMLSchema#string

Nancy J Ganson

http://www.w3.org/2001/XMLSchema#string

Susan J Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Introduction and overview of peptide and protein pegylation

Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase

Molecular identification of a danger signal that alerts the immune system to dying cells

Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Tria

Effect of pegylation on pharmaceuticals.

IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.

Cellular mechanisms governing cross-presentation of exogenous antigens.

Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.

A specific enzyme defect in gout associated with overproduction of uric acid

P2888

P304

R12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR1861

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7414393

http://www.w3.org/2001/XMLSchema#string

P6179

1007745350

http://www.w3.org/2001/XMLSchema#string

P698

16356199

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

1526556

http://www.w3.org/2001/XMLSchema#string